- Global Pharma News & Resources

Growing geriatric population will boost the eosinophilic esophagitis drug market, forecast to reach US$ 135 Mn by 2025 with a CAGR of 6%

Noida, Uttar Pradesh, India, March 12 2021 (Wiredrelease) Report Ocean Pvt Ltd –:The growing geriatric population, rising demand for early detection of diseases, and increasing prevalence of target diseases are key factors driving the market’s growth. The overall market for eosinophilic esophagitis drugs is also witnessing a surge in demand owing to increasing point-of-care testing and personalized medicine. Besides this, the market also benefited from increasing government funding to improve healthcare facilities and increase focus on innovations from the market players. Following these promising developments, the Global Eosinophilic Esophagitis Drug Market is estimated to see healthy growth, pegged at a CAGR of around 6% throughout the forecast period 2020-2025.

Request Sample Report at:

Considering the current scenario, around 160,000 people suffer from eosinophilic esophagitis and are treated with un-approved off-label drugs and diet modifications in the US alone. Among these, about 50,000 have a recurrent course of treatment. Part A of the phase 3 trial was the randomized, double-blind, placebo-controlled trial in which 81 patients met both primary and secondary endpoint. Moreover, the enrolled patients were administered a weekly dose of Dupixent 300 mg over a treatment period of 24-weeks. Furthermore, the patients examined had a reduction in primary symptoms, esophagus inflammation, and reduced eosinophil count on the esophagus mucosal membrane.

In August 2019, AstraZeneca publicized that the FDA had approved an orphan drug designation to its drug candidate Fasenra (benralizumab), used in the EoE treatment. FDA also gives this status to drug candidates who are intended to prevent rare disorders/diseases, affecting less than 200,000 individuals in the US market. Drug depletes eosinophils present in both blood and connective tissue during eosinophilic esophagitis treatment and is undergoing clinical trials to test its specificity and efficacy. Currently, there are no FDA-approved drugs for eosinophilic esophagitis treatment. Such approvals are expected to create completion intensity in the global market. Such licenses are also crucial for the companies and estimated to create lucrative opportunities in the market during the forecast period.

North America has developed as the most prominent region throughout the forecast period

North America witness a high growth in the eosinophilic esophagitis drug consumption in 2020. Also, the region witness growth in terms of significant developments, revenue generation, and eosinophilic esophagitis drugs opportunities. The increasing presence and investments from several biosciences and pharmaceutical companies and the availability of well-established healthcare infrastructure in the domestic market are account for the substantial growth during the forecast period. The market in Europe is estimated to grow gradually, closely followed by the Asia Pacific region. Increasing government efforts to improve patients’ care and rising investments by public-private organizations drive market growth in these regions.

Segmentation Overview of the Global Eosinophilic Esophagitis Drug Market

The eosinophilic esophagitis drug market has been segmented into Product Type, Distribution Channel, and Application. These major market segments are further categorized into various sub-segments to study the market in detail.

By Product Type Outlook (Budesonide, Fluticasone, Others)

By Distribution Channel Outlook (Hospital Pharmacy, Retail Pharmacy, Others)

By Application Outlook (Hospitals, Clinics, Drugstore)

Key Players Insights

Regeneron Pharmaceuticals, Bristol-Myers Squibb, Takeda (Shire), Adare Pharmaceuticals, Inc., DBV Technologies, Arena Pharmaceuticals, Dr. Falk Pharma GmbH, Allakos, Inc., and Ception Therapeutics, among others, are some significant players included in the research study of the global eosinophilic esophagitis drug market. 

For Purchase Enquiry at:

This content has been published by Report Ocean Pvt Ltd company. The WiredRelease News Department was not involved in the creation of this content. For press release service enquiry, please reach us at

Editor Details

Last Updated: 12-Mar-2021